سعر داكلافيروكيرل 60 مجم 28 قرص 2022

Egyptian daclatasvir 60 mg film-coated tablets (Marcyrl Pharmaceutical Industries) for use in chronic hepatitis C regimens (typically with sofosbuvir ± ribavirin).

• Chronic HCV genotype 1 or 3 infection, used with sofosbuvir with or without ribavirin (not as monotherapy).Population: Adults with HCV GT1 or GT3FDA / Drugs@FDA

• Most common (≥10%) with sofosbuvir: headache, fatigue; with sofosbuvir+ribavirin: headache, anemia, fatigue, nausea.International label, same formulation · FDA / Drugs@FDA

• Concomitant strong CYP3A inducers including phenytoin, carbamazepine, rifampin, and St John's wort.International label, same formulation · FDA / Drugs@FDA

• Boxed warning: test for HBV before HCV DAA therapy; HBV reactivation can cause fulminant hepatitis, failure, death.International label, same formulation · FDA / Drugs@FDA
• Serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone; coadministration not recommended.International label, same formulation · FDA / Drugs@FDA

• Strong CYP3A inducers (phenytoin, carbamazepine, rifampin, St John's wort)MajorMay decrease daclatasvir exposure and cause loss of virologic response; contraindicated.FDA / Drugs@FDA
• Amiodarone (with sofosbuvir-containing regimen)MajorSerious symptomatic bradycardia reported; coadministration with daclatasvir+sofosbuvir not recommended.FDA / Drugs@FDA

• No adequate human data; animal embryofetal toxicity at high exposures; if used with ribavirin, pregnancy contraindicated for patient and male partners.International label, same formulation · FDA / Drugs@FDA
• Unknown if present in human milk; present in rat milk; weigh benefits vs potential adverse effects; ribavirin lactation rules also apply if used.International label, same formulation · FDA / Drugs@FDA

• Daclatasvir: Inhibits HCV non-structural protein 5A (NS5A), an essential component of the viral replication complex, blocking viral RNA replication and virion assembly.